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Abstract
Background: Increased mortality among men on antiretroviral therapy (ART) has been documented but remains poorly
understood. We examined the magnitude of and risk factors for gender differences in mortality on ART.
Methods and Findings: Analyses included 46,201 ART-naı¨ve adults starting ART between January 2002 and December 2009
in eight ART programmes across South Africa (SA). Patients were followed from initiation of ART to outcome or analysis
closure. The primary outcome was mortality; secondary outcomes were loss to follow-up (LTF), virologic suppression, and
CD4+ cell count responses. Survival analyses were used to examine the hazard of death on ART by gender. Sensitivity
analyses were limited to patients who were virologically suppressed and patients whose CD4+ cell count reached .200
cells/ml. We compared gender differences in mortality among HIV+ patients on ART with mortality in an age-standardised
HIV-negative population. Among 46,201 adults (65% female, median age 35 years), during 77,578 person-years of follow-up,
men had lower median CD4+ cell counts than women (85 versus 110 cells/ml, p,0.001), were more likely to be classified
WHO stage III/IV (86 versus 77%, p,0.001), and had higher mortality in crude (8.5 versus 5.7 deaths/100 person-years,
p,0.001) and adjusted analyses (adjusted hazard ratio [AHR] 1.31, 95% CI 1.22–1.41). After 36 months on ART, men were
more likely than women to be truly LTF (AHR 1.20, 95% CI 1.12–1.28) but not to die after LTF (AHR 1.04, 95% CI 0.86–1.25).
Findings were consistent across all eight programmes. Virologic suppression was similar by gender; women had slightly
better immunologic responses than men. Notably, the observed gender differences in mortality on ART were smaller than
gender differences in age-standardised death rates in the HIV-negative South African population. Over time, non-HIV
mortality appeared to account for an increasing proportion of observed mortality. The analysis was limited by missing data
on baseline HIV disease characteristics, and we did not observe directly mortality in HIV-negative populations where the
participating cohorts were located.
Conclusions: HIV-infected men have higher mortality on ART than women in South African programmes, but these
differences are only partly explained by more advanced HIV disease at the time of ART initiation, differential LTF and
subsequent mortality, and differences in responses to treatment. The observed differences in mortality on ART may be best
explained by background differences in mortality between men and women in the South African population unrelated to
the HIV/AIDS epidemic.
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Introduction
South Africa has the largest antiretroviral therapy (ART)
programme worldwide. The programme has undergone rapid
expansion with nearly 1.64 million adults initiating ART since
2004 [1]. Given the unprecedented scale of this initiative there is
an urgent need to evaluate the outcomes of the programme in
order to improve delivery of services. There is particular interest in
gender differences in ART programme access and survival.
Disproportionately more women than men have accessed ART
in sub-Saharan Africa [2,3]. Studies from Europe and North
America suggest a higher risk of death on ART for women than
men [4]; in contrast, across sub-Saharan Africa men appear to
experience greater mortality than women on treatment [5–8].
A range of possible explanations for gender differences in
mortality on ART have been suggested but there has been no
comprehensive evaluation of the putative mechanisms. Baseline
characteristics strongly predict mortality on ART [9–11], and men
initiating ART in many African programmes have more advanced
HIV disease than women [2,6,12]. In addition, loss to follow-up
(LTF) is associated with mortality [13], and men are more likely to
become LTF than women in many settings [14,15]. Evidence
regarding gender differences in immunologic and virologic re-
sponses is mixed [4]. It is vital to understand such differentials in
order to improve health outcomes in this large and rapidly
expanding health service.
We examined the magnitude of, and risk factors for, gender
differences in mortality. We included data from eligible adults
starting ART in the South African sites of the International
Epidemiologic Databases to Evaluate AIDS Southern Africa
(IeDEA-SA) collaboration between 2002 and 2009, representing
about 10% of all patients enrolled nationally during this period
[1]. We hypothesized that increased mortality in men on ART, if
present, would be explained by differences in: (1) baseline
characteristics; (2) differential risk of LTF and subsequent
mortality; and/or (3) gender differences in virologic and immu-
nologic responses.
Methods
Study Design, Population, and Eligibility Criteria
The South African cohorts of IeDEA-SA have been described in
detail elsewhere [16,17]. Briefly, the collaboration includes eight
adult cohorts providing ART services in three of the most
populous provinces (Gauteng, KwaZulu-Natal, and Western
Cape). Cohorts range in size and are predominantly govern-
ment-funded and follow national HIV treatment guidelines. The
multicentre cohort is broadly representative of patients accessing
public sector ART in rural and urban centres. This retrospective
cohort analysis included all ART-naı¨ve HIV-positive adults ($16
and #80 y) who initiated ART between 2002 and 2009.
Variables and Definitions
Baseline characteristics measured immediately before ART
initiation included demographics (age, gender), available measures
of HIV disease severity (CD4+ cell count, WHO stage, HIV viral
load), clinical and laboratory characteristics (haemoglobin,
weight), and calendar year of ART initiation. CD4+ cell count
and viral load measures were taken after 12, 24, and 36 mo on
ART. When measurements were not available at these time
points, we included the closest laboratory measurement within a 3-
mo period on either side of the date as available. All laboratory
tests were performed by the South African National Health
Laboratory Services.
We treated the following variables as categorical: age (16–24,
25–34, 35–44, 45+ y), CD4+ cell count (0–24, 25–49, 50–99, 100–
199, 200+ cells/ml), WHO stage (I and II, III, IV), and
haemoglobin; we treated weight and log viral load as continuous
variables. Because of gender variability in haemoglobin levels, we
generated a categorical variable (anaemia) from the haemoglobin
level (measured in g/dl), which was defined as: none: females
.11.9, males .13.1; mild: females 10–11.9, males 11–13.1;
moderate: females 8.1 to ,10, males 8.1 to ,11; severe: ,8.1
[18]. We defined virologic failure as a viral load measurement
.400 copies/ml.
The primary outcome was mortality. Secondary outcomes were
LTF, virologic suppression, and CD4+ cell count responses.
Deaths were identified by the sites or by linkage to the National
Population Register (NPR) of the Department of Home Affairs.
Transfers were recorded by programmes and observation time was
right-censored at the date of transfer. Patients were defined as LTF
if there was no patient contact between analysis closure and
database closure. Analysis closure preceded database closure by
6 mo to allow patients to meet the LTF definition. LTF date was
defined as the last patient contact date. In order to differentiate
between patients who were truly LTF and patients who had died
within 3 mo of being LTF (misclassified deaths), we used linkage
information to trace patients LTF with South African civil
identification (ID) numbers (Figure S1). Patients who had a date
of death within 3 mo after LTF were defined as misclassified
deaths. Those with ID numbers who were not found in the
population register in this period were defined ‘‘true’’ LTF [19].
For patients who started ART but had no further contact, we
added 1 d of follow-up to allow their inclusion in survival analyses.
Missing Data
On the basis of the assumption that data were likely missing at
random, we used multiple imputation [20] by chained equation
methods [21] to impute missing baseline data. We multiply
imputed (20 times) baseline CD4+ cell count, WHO stage, viral
load, weight, and haemoglobin. The multiple imputation models
included all measured variables.
Given that a high proportion of patients LTF are likely to have
died [13], we used inverse probability weighting [22] to correct
mortality and LTF for missing deaths among those defined as
LTF. Briefly, LTF patients with ID numbers (approximately 50%)
were linked to the South African National Population Register to
determine their true vital status (and date of death if deceased) and
weighted to represent all patients LTF, enabling more accurate
estimates of vital status.
Analysis
Data were analysed using STATA 11.0 (STATA Corporation).
Baseline characteristics were described with summary statistics
(median, interquartile range [IQR] and proportions) by gender.
Differences between proportions and medians were tested with
Pearson’s chi-squared test for proportions or the two-sample
Wilcoxon rank-sum test. Two-sided statistical tests were used at
alpha = 0.05. Time to death and time to ‘‘true’’ LTF were
analysed from date of ART initiation using Kaplan-Meier curves.
Cox’s proportional hazards regression models were used to
assess crude and adjusted associations between patient character-
istics and outcomes. All available plausible demographic and
clinical variables were considered potential confounders and were
included in multivariable models if they altered the association
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between gender and mortality or were significantly associated with
the outcome under study. Results are presented as hazard ratios
(HRs) with a 95% CI by duration on ART. The proportional
hazards assumption was confirmed by testing gender/time and
gender/log time interaction terms. We undertook sensitivity
analyses limited to patients who were virologically suppressed
and patients whose CD4+ cell count reached .200 cells/ml. We
explored heterogeneity in analyses stratified by cohort. The gender
mortality ratio was defined as the male divided by the female
mortality rate.
To compare gender differences in our cohort with expected
gender differences in the HIV-negative population, we calculated
HIV-negative mortality in the South African male population and
female population, age-standardised to our patients. Age-specific
HIV-negative mortality rates in males and females were obtained
from the Actuarial Society of South Africa (ASSA) estimates of
non-HIV mortality in the year 2005 [23], which are derived from
vital registration statistics as well as census and survey data (further
explanation of the derivation of these rates is provided in Text S1).
All IeDEA-SA sites obtained ethical approval from relevant
local institutions before contributing anonymised patient data to
this collaborative analysis. In addition, the collaboration has
approval from the University of Cape Town Human Research
Ethics Committee to receive and analyse these collaborative data.
Results
Among 58,124 patients assessed for eligibility, 11,923 were
ineligible for the following reasons: age ,16 or .80 y (n= 4,344),
missing or invalid dates (birth, ART initiation, last visit, outcomes)
(n= 4,770), non-ART naı¨ve (n= 2,806), unknown gender (n= 3)
(Figure 1). This analysis included 46,201 adults who started ART
between 1 January 2002 and 31 December 2009 (median age
35 y; 65% female) (Table 1), contributing a total of 77,578 person-
years of follow-up. Men had a shorter median time to death (483
versus 532 person-days) and ‘‘true’’ LTF (434 versus 495 person-
days) than women. By the end of the study period, 29,901 patients
were still on ART, 67% (n= 20,151) of these female.
At initiation of ART, men were older than women (38 versus
33 y) and had lower median CD4+ cell counts (85 versus 110
cells/ml) (Table 1). Men were more likely than women to have a
CD4+ cell count ,50 cells/ml (34% versus 26%) and to be
classified WHO stage III/IV (86% versus 77%). The median
haemoglobin level was similar for men and women (12 versus
11 g/dl). Among females initiating ART, 7% were pregnant.
Gender differences in baseline characteristics were consistent
across all the eight cohorts (Figure 2).
Gender and Mortality
In total, after correction via linkage to the National Population
Register, there were 3,946 deaths, 57% among women. Men had
a higher risk of mortality (Figure 3). The crude mortality on ART
was higher for men than women: 8.5 versus 5.7/100 person-years,
unadjusted HR 1.46 (1.37–1.56), p,0.001. In multivariable
analysis, after adjusting for baseline age, cohort, CD4+ cell count,
WHO stage, log viral load, anaemia, and weight, men had a 31%
higher risk of death than women (adjusted HR [AHR] 1.31, 95%
CI 1.22–1.41) (Table 2). Other baseline factors associated with
mortality were age .35 y, CD4+ cell count, WHO stage,
anaemia, weight, and viral load (Table S1). The association
between gender and death persisted with increasing duration on
ART. In a stratified analysis, the elevated risk of death for men
compared with women was consistent across cohorts (Figure 2).
Excluding WHO stage from the adjusted model did not change
our main finding (AHR 1.34, 95% CI 1.25–1.44). There was no
evidence of an interaction between gender and age.
Gender and Loss to Follow-up
Using our initial definition, 8,303 adults were suspected LTF, of
whom 61% were female (Figure S1). We were able to ascertain the
vital status of 4,389 patients who had ID numbers (61% female).
Among those patients who were LTF without ID numbers and
whose outcomes could not be ascertained (n= 3,914), 62% were
female. After linkage to the NPR, we identified 746 patients who
had died within 3 mo of being suspected LTF. We regarded these
as misclassified deaths (57% female). After correction for these
deaths, a total of 3,643 patients were defined as ‘‘true’’ LTF, 61%
female.
Men were more likely than women to experience ‘‘true’’ LTF
(Figure 4). The crude ‘‘true’’ LTF rate was 10.03/100 person-
years, lower among women than men (9.18 versus 11.77/100
person-years, respectively). In multivariable analysis, after adjust-
ing for baseline age, cohort, CD4+ cell count, WHO stage,
anaemia, weight, viral load, and calendar year of initiation, men
were more likely to be truly LTF than women (AHR 1.20, 95% CI
1.12–1.28). Within each cohort, the trend towards increased risk of
‘‘true’’ LTF was consistent but estimates were less precise. Using
linkage to the NPR, we then explored mortality among those who
were truly LTF with ID numbers (i.e., still alive 3 mo after being
suspected LTF). We found no gender difference in the hazard of
death among those patients who were truly LTF (AHR 1.04, 95%
CI 0.86–1.25).
Gender and Virologic and Immunologic Responses to
ART
There was a high proportion of virologically suppressed patients
at 12, 24, and 36 mo on ART, with no evident gender difference
in proportions (Table 3). When analysis of mortality was restricted
to individuals who were virologically suppressed at 12 mo, men
still had a higher risk of death than women (AHR 1.38, 95% CI
1.07–1.79). Women initiating ART had a higher baseline CD4+
cell count and better CD4+ cell count responses than men over
36 mo (Figure S2). The median incremental CD4+ cell gains for
women and men at 12, 24, and 36 mo were 179 versus 145, 89
versus 70, and 63 versus 39 cells/ml, respectively (Table 3,
p,0.001 for all comparisons). In a sensitivity analysis limited to
patients who had reached a CD4+ cell count $200 after a year on
ART, the gender difference in mortality persisted (AHR 1.37,
95% CI 1.03–1.83) (unpublished data).
Gender and Non-HIV Mortality
Given the persistence of the gender differential in mortality
among patients on ART, we compared this to the background
gender differential in mortality in the South African population.
Figure 5 shows that the gender mortality ratio among patients on
ART appears to be smaller than the age-standardised HIV-
negative mortality ratio for men versus women in South Africa.
HIV-negative men with the same age distribution as that in the
ART cohort would be expected to die at twice the rate in HIV-
negative women of the same age, compared with our AHR of 1.31
on ART. With increasing duration of ART, the contribution of
expected non-HIV mortality to observed mortality increased from
an estimated 5% in the first 6 mo to 36% after 36 mo among men
and from 3% to 25% among women during the same periods
(Table 4). In further analyses stratified by age (16–34 and 35+ y),
expected non-HIV mortality accounted for a larger proportion of
deaths in the older men than in the younger men (Table S2). One
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Figure 1. Patient flowchart. Description of a combined cohort of adult patients initiating public sector ART in South Africa, 2002–
2009.
doi:10.1371/journal.pmed.1001304.g001
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exception was the proportion of observed male mortality attribut-
able to non-HIV mortality at .36 mo, likely to be random error
due to the small number of deaths at the longest duration. In both
age groups, non-HIV mortality contributed more substantially to
male mortality than to female mortality. In addition, over all periods
on ART, although the expected ratio of male to female non-HIV
deaths differed at younger and older ages, all ratios were greater
than the male to female ratio of observed mortality on ART.
Table 1. Patient characteristics among 46,201 adults initiating public-sector ART in South Africa, 2002–2009.
Baseline Characteristica Males (n=16,108, 35%) Females (n=30,093, 65%) Total (n=46,201)
Age, median (IQR), years 37.5 (32.6–43.9) 33.4 (28.6–39.9) 34.9 (29.7–41.5)
16–24 n (%)b 442 (3) 3,124 (11) 3,566 (8)
25–34 5,639 (35) 14,214 (47) 19,853 (43)
35–44 6,486 (40) 8,810 (29) 15,296 (33)
$45 3,541 (22) 3945 (13) 7,486 (16)
CD4+ cell count, median (IQR), cells/ml 85 (33–153) 110 (48–171) 101 (42–166)
0–24 n (%) 2,785 (20) 3,770 (15) 6,555 (16)
25–49 1,965 (14) 2,832 (11) 4,797 (12)
50–99 3,002 (22) 5,267 (20) 8,269 (21)
100–199 4,798 (35) 10,772 (41) 15,570 (39)
$200 1,321 (10) 3,353 (13) 4,674 (12)
Missing data 14% 14% 14%
WHO stage, n (%) 5,538 (34) 11,290 (38) 16,828 (36)
I and II 790 (14) 2,704 (24) 3,494 (21)
III 3,221 (58) 5,933 (53) 9,154 (54)
IV 1,527 (28) 2,653 (24) 4,180 (25)
Missing data 66% 62% 64%
Viral load, n (%) 8,092 (50) 14,876 (49) 22,968 (50)
Log10 copies/ml, median (IQR) 4.9 (4.4–5.3) 4.8 (4.2–5.3) 4.8 (4.3–5.3)
Missing data 50% 51% 50%
Haemoglobin, n (%) 11,714 (73) 20,237 (67) 33,239 (72)
Median (IQR), g/dl 12 (10.2– 13.8) 10.9 (9.5–12) 11.1 (9.8–12.7)
Missing data 27% 33% 28%
Anaemia, n (%) 11,714 (73) 20,237 (67) 33,239 (72)
None 3,813 (33) 4,968 (23) 8,781 (26)
Mild 5,638 (48) 12,997 (60) 18,635 (56)
Moderate/severe 2,263 (19) 3,560 (17) 15,823 (18)
Weight, n (%) 12,740 (79) 23,788 (79) 36,528 (79)
Median (IQR), kg 60 (53.4–67.1) 59 (51–68) 59 (52–68)
Pregnant, n (%)c — 1,494 (7%) —
Calendar year of ART initiation
2002 and 2003 439 (3) 856 (3) 1,310 (2.7)
2004 1,338 (8) 2,847 (9) 4,271 (8.6)
2005 2,743 (17) 5,568 (19) 8,640 (17.5)
2006 4,345 (27) 7,851 (26) 12,992 (26.3)
2007 3,629 (23) 6,506 (22) 10,944 (22.1)
2008 2,323 (14) 4,398 (15) 7,479 (15.1)
2009 1,291 (8) 2,067 (7) 3,836 (7.8)
Follow-up, median (IQR), person-days
Time to death 483 (172–877) 532 (216–918) 515 (200–905)
Time to ‘‘true’’ LTF 434 (142–827) 495 (185–879) 476 (170–864)
aAll differences between men and women were statistically significant (p,0.001).
bn (%) reflects the number (percentage) of patients with values for this variable.
cData from five cohorts.
doi:10.1371/journal.pmed.1001304.t001
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Discussion
These analyses demonstrate that among patients initiating ART
between 2002 and 2009 at sites across South Africa, men had
higher mortality than women. We hypothesized that gender
differences in mortality would be explained by differences in
baseline characteristics, LTF and subsequent mortality, and/or
virologic and immunologic responses. However, we found that the
increased mortality risk among men persisted throughout each
analysis, including after adjustment for measures of HIV disease at
the time of ART initiation, in the subset of patients who achieved
virologic suppression, and among patients with good immune
responses to treatment.
There is a large and growing body of work on gender and
ART in developing countries, much of which documents the
same association repeatedly [24]: disproportionately fewer men
than women access ART [2,3,25], and there is higher mortality
among men than women on ART [5,8,15,16,26,27]. Such
studies typically speculate as to the possible mechanisms
underlying the observed associations. Putative mechanisms
include: poor health-seeking behaviours among men leading to
more advanced disease at the time of ART initiation, differential
rates of LTF leading to higher mortality, behavioural factors
such as poor adherence, and/or biologic factors such as gender
differences in immunologic responses to ART. However, there
have been few systematic attempts to evaluate each of these
possible mechanisms.
In this study, women comprised the majority of adults starting
ART across the country. In the early years of ART programmes
there were understandable concerns that due to gender imbal-
ances, women may have reduced access to ART services [28].
Contrary to this, however, there is mounting evidence that men
appear disadvantaged in their access to ART programmes.
Numerous papers and a systematic review have suggested gender
inequalities in ART access, particularly in sub-Saharan Africa
[2,3,8], and ART initiation in South Africa, relative to ART need,
is substantially higher in women than in men [1].
Among patients who do start ART, late presentation has been
cited as one of the main reasons for increased male mortality in
ART programmes [4–6,8]. In sub-Saharan Africa, men appear to
initiate ART at older ages and with more advanced HIV disease
than women [2,3,6,16], and markers of advanced HIV disease
at the time of ART initiation strongly predict early mortality on
ART [9,12,29–31]. However, in our multivariable models we
found that adjustment for baseline characteristics accounted for
only part of the gender difference in mortality, and that the gender
differentials in mortality continued to appear for several years
after ART initiation. The reasons for men’s later entry into ART
Figure 2. Male versus female mortality. Baseline characteristics and adjusted hazard ratios for male versus female mortality, by
cohort. Adjusted for baseline age, CD4+ cell count, WHO stage, anaemia, weight, and viral load. Male versus female is reported as M:F.
doi:10.1371/journal.pmed.1001304.g002
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programmes are poorly understood but frequently are attributed
to gender differences in health-seeking behaviour or in routes of
referral [32]. An alternate and more compelling explanation may
be that while prioritising maternal and child health services in
many public health systems, men’s primary health care needs may
have been neglected [32–35], a possibility that warrants further
research attention.
We then assessed the role of LTF in explaining mortality
differentials. Increased mortality among patients LTF, especially
within the first 3 mo after LTF, has been well documented [19,36–
40]. In turn, it is plausible that if males are more likely to be LTF,
this could explain their elevated mortality risk. Through linkage to
the South African Population Register we were able to identify a
group of patients who were truly LTF, and to trace their vital
status after being LTF. Although men were more likely to be LTF
compared with women, we found no gender difference in
mortality after LTF, and deaths after LTF contributed only a
small proportion of all deaths. Thus in these data, LTF alone did
not appear to explain men’s increased mortality.
Behavioural factors such as treatment adherence could also help
to explain the observed increased male mortality on ART. Poor
adherence to ART, measured by virologic non-suppression,
significantly increases the risk of mortality on treatment. We found
no apparent gender difference in virologic suppression, although
previous studies have suggested that adherence may vary by gender
[41]. Of note, this finding was consistent across all cohorts, and in a
sensitivity analysis restricted to patients who were virologically
suppressed at 12 mo, men still had a higher risk of subsequent death
than women. As a result, gender differences in adherence to
treatment do not appear to explain differences in mortality.
Biologic differences between men and women have been
suggested as shaping immunologic responses to ART and
mortality risk. We found that women had higher CD4+ cell
counts at ART initiation than men, and slightly better absolute
CD4+ cell increases on treatment. These data are in line with results
from two collaborative studies in sub-Saharan Africa that
documented greater immune recovery in women than in men,
with gender-based differences increasing with time on ART [43,44].
However, even among patients with similar immunologic responses
by 1 y on treatment, the gender difference in mortality persisted.
In these data, the finding of persistently increased male
mortality for up to 3 y on ART does not appear to be explained
entirely by baseline differences in HIV disease status, variation in
LTF, differences in virologic suppression, or sex-linked differences
in immune responses to treatment. Having thus refuted our a
priori hypotheses, we explored alternate explanations for the
Figure 3. Mortality by gender and ART duration. Kaplan-Meier estimates of mortality by gender and duration on ART, corrected via linkage to
the National Population Register.
doi:10.1371/journal.pmed.1001304.g003
Table 2. Crude and adjusted associations between male
gender and mortality by duration on ART.
Duration Crude HR AHR
0–12 mo 1.28 (1.09–1.51) 1.10 (0.93–1.31)
12–24 mo 1.63 (1.37–1.94) 1.36 (1.05–1.78)
24–36 mo 1.62 (1.22–2.14) 1.39 (0.94–2.06)
.36 mo 1.71 (1.08–2.70) 1.35 (0.76–2.38)
Total time 1.46 (1.37–1.56) 1.31 (1.22–1.41)
Multivariable models adjusted for cohort, age, CD4+ cell count, WHO stage, anaemia,
weight, and log viral load at ART initiation. 95% CI in brackets after HR and AHR.
doi:10.1371/journal.pmed.1001304.t002
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observed association. We examined evidence for gender differ-
ences in non-HIV adult mortality in South Africa, and found
pronounced differences that appear independent of the HIV/
AIDS epidemic. Specifically, evidence from actuarial modelling
suggests that HIV-negative South African men in the same age
groups as our study population have twice the mortality risk of
women, although the male-female differences tend to be more
pronounced in young adults than in older adults. This pattern is
not unique to South Africa: similar trends are seen elsewhere in
Africa and worldwide [44–48]. This evidence places these data,
and previous studies showing increased mortality among men in
ART services across Africa, into perspective: among patients on
ART, men have an increased risk of death on ART compared to
women, but this same phenomenon operates in HIV-negative
individuals. In fact, in South Africa the mortality ratio for men
versus women on ART appears to be somewhat smaller than the
age-standardised ratio for men versus women estimated for the
HIV-negative population. Gender differentials in mortality of
Figure 4. ‘‘True’’ loss to follow-up by gender and ART duration. Kaplan-Meier estimates of ‘‘true’’ LTF by gender and duration on ART.
doi:10.1371/journal.pmed.1001304.g004
Table 3. Virologic and immunologic responses by gender and duration on ART.
Measurement 12 mo 24 mo 36 mo
Female
(n=21,032)
Male
(n=10,702)
Female
(n=13,232)
Male
(n=6,826)
Female
(n=7,440)
Male
(n=3,950)
Viral load tests
Total tested, n 13,529 6,600 8,280 3,798 4,225 1,958
Proportion suppresseda 0.87 0.86 0.86 0.86 0.93 0.95
Proportion missing data 0.36 0.38 0.37 0.44 0.43 0.50
CD4+ cell counts
Total tested, n 15,882 7,752 9,510 4,438 4,728 2,168
Median, cells/ml 294 239 381 315 437 359
(IQR) (204 to 403) (164 to 337) (268 to 512) (217 to 431) (313 to 582) (243 to 493)
Median CD4+ cell count increaseb 179 145 89 70 63 39
(IQR) (100 to 273) (78 to 223) (13 to 175) (9 to 141) (222 to 147) (221 to 114)
Proportion missing data 0.24 0.28 0.28 0.35 0.36 0.45
aProportion suppressed is the proportion of patients with available data who achieved a viral load #400 copies/ml.
bMedian CD4+ cell count increase is the difference in CD4+ cell count at each time point between this measure and the measure taken at the previous time point; all
differences between men and women were statistically significant, p,0.001.
doi:10.1371/journal.pmed.1001304.t003
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HIV-negative individuals are well-documented in South Africa
and include an increased burden of mortality among younger men
due to traumatic causes and non-HIV tuberculosis [49]. It is
possible that through accessing ART services, men and women
may access other preventive and curative services that reduce non-
HIV mortality. While these findings are intriguing, it is important
to recognize that our original hypotheses did not include gender
differences in non-HIV mortality, and this phenomenon clearly
requires further investigation.
Observational studies of patients on ART face major
constraints in terms of mortality ascertainment, LTF, and
missing measurements. Most cohort analyses from sub-Saharan
Africa—and especially large collaborative analyses—have limit-
ed ability to ascertain true outcomes as they have little capacity
Figure 5. Male versus female mortality ratios over time. Solid line, observed mortality ratio for men versus women on ART. Dotted line, age-
standardised HIV-negative mortality ratio for men versus women in South Africa.
doi:10.1371/journal.pmed.1001304.g005
Table 4. Observed crude mortalitya, age-standardised HIV-negative mortalitya, and expected non-HIV mortality as a percentage of
observed mortality among men and women, by duration on ART.
Gender Mortality Duration on ART
0–6 mo 6–12 mo 12–24 mo 24–36 mo .36 mo
Male Observed mortality (crude) 19.13 6.19 4.52 3.43 2.86
HIV-negative mortality (age-standardized) 0.90 0.92 0.95 0.98 1.03
Expected non-HIV mortality as a percentage of
observed mortality
5% 15% 21% 29% 36%
Female Observed mortality (crude) 13.16 4.82 2.78 2.12 1.69
HIV-negative mortality (age-standardized) 0.36 0.37 0.38 0.39 0.42
Expected non-HIV mortality as a percentage of
observed mortality
3% 8% 14% 19% 25%
doi:10.1371/journal.pmed.1001304.t004
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to follow patients actively [6]. In addition, few African countries
have high quality vital statistics [47,50,51]. In turn, most large
ART programmes have difficulty confirming patients’ true vital
status [52], and in the absence of reliable death registration,
researchers have undertaken targeted tracing studies [40]. In
South Africa, the National Population Register captures nearly
90% of adult deaths [53]. Through our linkage with this register,
we are able to distinguish between ‘‘true’’ LTF and unrecognised
mortality in many patients. Moreover, consistency of findings
across different cohorts strengthens the generalizability of our
results.
Interpretation of these results is subject to several important
limitations. These data come from multiple service delivery
programmes from across South Africa, and there is a substantial
amount of missing data in this analysis. For example, South
African national identity numbers were only available for 53% of
those who were suspected to be LTF, and it is possible that there
are systematic differences between patients with and without ID
numbers for which we have not accounted. There was also a high
proportion of missing values for WHO stage and viral load; we
tried to address this with multiple imputation and sensitivity
analyses confirming our main findings. Missing data on specific
risk factors for mortality, particularly prevalent tuberculosis at
ART initiation [54], further limited this analysis. Finally, we did
not observe mortality in HIV-negative populations where the
participating cohorts are located, and instead used a national-level
actuarial model to estimate mortality in men and women who are
HIV-negative. These findings are likely to be generalizable to the
South African national ART programme, and potentially to other
parts of the region, but further investigation in other settings is
warranted.
In summary, there have been concerns raised about the
presence of gender differences in mortality on ART in South
Africa and many other parts of the continent. In this study we
systematically explored this phenomenon and found that none of
the explanations posited for this association adequately explains
the increased mortality observed among men on ART. Instead,
the observed differences in mortality on ART may be best
explained by background differences in death rates between men
and women in the South African population, unrelated to the
HIV/AIDS epidemic.
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Editors’ Summary
Background. About 34 million people (most living in low-
and middle-income countries) are currently infected with
HIV, the virus that causes AIDS. HIV destroys CD4 lympho-
cytes and other immune system cells, leaving infected
individuals susceptible to other infections. Early in the AIDS
epidemic, most HIV-infected people died within 10 years of
becoming infected. Then, in 1996, antiretroviral therapy
(ART)—cocktails of drugs that keep HIV in check—became
available. For people living in affluent countries, HIV/AIDS
became a chronic condition. However, ART was expensive
and, for people living in poorer countries, HIV/AIDS remained
a fatal illness. In 2003, this situation was declared a global
emergency, and governments and international agencies
began to implement plans to increase ART coverage in
resource-limited countries. Since then, ART programs in
these countries have grown rapidly. In South Africa, for
example, about 52% of the 3.14 million adults in need of ART
were receiving an ART regimen recommended by the World
Health Organization by the end of 2010.
Why Was This Study Done? The outcomes of ART
programs in resource-limited countries need to be evaluated
thoroughly so that these programs can be optimized. One
area of concern to ART providers is that of gender
differences in survival among patients receiving treatment.
In sub-Saharan Africa, for example, men are more likely to die
than women while receiving ART. This gender difference in
mortality may arise because men initiating ART in many
African ART programs have more advanced HIV disease than
women (early ART initiation is associated with better
outcomes than late initiation) or because men are more
likely to be lost to follow-up than women (failure to continue
treatment is associated with death). Other possible explana-
tions for gender differentials in mortality on ART include
gender differences in immunologic and virologic responses
to treatment (increased numbers of immune system cells
and reduced amounts of virus in the blood, respectively). In
this multicenter cohort study, the researchers examine the
size of, and risk factors for, gender differences in mortality on
ART in South Africa by examining data collected from adults
starting ART at International Epidemiologic Databases to
Evaluate AIDS South Africa (IeDEA-SA) collaboration sites.
What Did the Researchers Do and Find? The researchers
analyzed data collected from 46,201 ART-naı¨ve adults who
started ART between 2002 and 2009 in eight IeDEA-SA ART
programs. At ART initiation, men had a lower CD4 count on
average and were more likely to have advanced HIV disease
than women. During the study, after allowing for factors
likely to affect mortality such as HIV disease stage at
initiation, men on ART had a 31% higher risk of dying than
women. Men were more likely to be lost to follow-up than
women, but men and women who were lost to follow-up
were equally likely to die. Women had a slightly better
immunological response to ART than men but virologic
suppression was similar in both genders. Importantly, in
analyses of mortality limited to individuals who were
virologically suppressed at 12 months and to patients who
had a good immunological response to ART, men still had a
higher risk of death than women. However, the gender
differences in mortality on ART were smaller than the gender
differences in age-standardized mortality in the HIV-negative
South African population.
What Do These Findings Mean? These analyses show
that among South African patients initiating ART between
2002 and 2009, men were more likely to die than women but
that this gender difference in mortality on ART cannot be
completely explained by gender differences in baseline
characteristics, loss to follow-up, or virologic and/or immu-
nologic responses. Instead, the observed gender differences
in mortality can best be explained by background gender
differences in mortality in the whole South African popula-
tion. Because substantial amounts of data were missing in
this study (for example, HIV disease stage was not available
for all the patients), these findings need to be interpreted
cautiously. Moreover, similar studies need to be done in
other settings to investigate whether they are generalizable
to the South African national ART program and to other
countries. If confirmed, however, these findings suggest that
the root causes of gender differences in mortality on ART
may be unrelated to HIV/AIDS or to the characteristics of ART
programs.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001304.
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N Information on the treatment of HIV/AIDS in South Africa is
available from the Southern African HIV Clinicians’ Society
N NAM/aidsmap provides basic information about HIV/AIDS
and summaries of recent research findings on HIV care and
treatment
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including informa-
tion on HIV/AIDS treatment and care, and on HIV/AIDS in
South Africa (in English and Spanish)
N WHO provides information about universal access to AIDS
treatment (in several languages); its 2010 ART guidelines
can be downloaded
N Information about the IeDEA-SA collaboration is available
N The Treatment Action Campaign provides information on
antiretroviral therapy and South African HIV statistics
N Patient stories about living with HIV/AIDS are available
through Avert; the nonprofit website Healthtalkonline also
provides personal stories about living with HIV, including
stories about taking anti-HIV drugs and the challenges of
anti-HIV drugs
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